Shares of ADMA Biologics ADMA increased in after-market trading after the company reported Q1 results.
Quarterly Results
Earnings per share were up 38.46% over the past year to ($0.16), which beat the estimate of ($0.17).
Revenue of $16,049,000 rose by 57.34% from the same period last year, which beat the estimate of $14,580,000.
Looking Ahead
ADMA Biologics hasn't issued any earnings guidance for the time being.
ADMA Biologics hasn't issued any revenue guidance for the time being.
Details Of The Call
Date: May 12, 2021
Time: 04:30 PM
ET Webcast URL: https://edge.media-server.com/mmc/p/zi9yyr2o
Price Action
Company's 52-week high was at $4.20
Company's 52-week low was at $1.45
Price action over last quarter: down 5.52%
Company Description
ADMA Biologics Inc is an end-to-end commercial biopharmaceutical company dedicated to manufacturing, marketing and developing specialty plasma-derived biologics for the treatment of immunodeficient patients at risk for infection and others at risk for certain infectious diseases. Its targeted patient populations include immune-compromised individuals who suffer from an underlying immune deficiency disorder or who may be immune-suppressed for medical reasons. The company sells plasma-derived intermediate fractions to certain customers, which are generated as part of its FDA-approved manufacturing process for IG and IVIG products. It also provides laboratory contracting services to certain customers and anticipate providing contract filling, labeling and packing services.
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Date | ticker | name | Actual EPS | EPS Surprise | Actual Rev | Rev Surprise |
---|
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.